Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER
Opana ER (oxymorphone) is an opioid drug available throughout the United States, and intravenous abuse of the crushed oral formulation has been associated with drug-induced thrombotic microangiopathy. In this abstract, we describe two young patients who lived together and used Opana ER intravenously...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2017/1623907 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556631375740928 |
|---|---|
| author | Kamia Thakur Vaibhav Agrawal Ashley Kass Lauren M. Dimarino R. Patrick Dorion Joseph Vadakara |
| author_facet | Kamia Thakur Vaibhav Agrawal Ashley Kass Lauren M. Dimarino R. Patrick Dorion Joseph Vadakara |
| author_sort | Kamia Thakur |
| collection | DOAJ |
| description | Opana ER (oxymorphone) is an opioid drug available throughout the United States, and intravenous abuse of the crushed oral formulation has been associated with drug-induced thrombotic microangiopathy. In this abstract, we describe two young patients who lived together and used Opana ER intravenously. Both presented with microangiopathic hemolytic anemia that mimicked thrombotic thrombocytopenic purpura (TTP). Treating this condition poses a clinical challenge, as it is difficult to distinguish it from TTP. The role for plasma exchange is not clear but can be used while awaiting the results of the ADAMTS-13 activity, but ultimately supportive care with drug discontinuation is the recommended therapy of choice. Patients should be counseled against Opana ER’s intravenous use, and users should be offered drug rehabilitation therapy. |
| format | Article |
| id | doaj-art-b0cdb7b0c66d4fb09749c5a5bb6befbd |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-b0cdb7b0c66d4fb09749c5a5bb6befbd2025-02-03T05:44:54ZengWileyCase Reports in Hematology2090-65602090-65792017-01-01201710.1155/2017/16239071623907Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ERKamia Thakur0Vaibhav Agrawal1Ashley Kass2Lauren M. Dimarino3R. Patrick Dorion4Joseph Vadakara5Geisinger Medical Center, Danville, PA, USAGeisinger Medical Center, Danville, PA, USAGeisinger Medical Center, Danville, PA, USAGeisinger Medical Center, Danville, PA, USAGeisinger Medical Center, Danville, PA, USAGeisinger Medical Center, Danville, PA, USAOpana ER (oxymorphone) is an opioid drug available throughout the United States, and intravenous abuse of the crushed oral formulation has been associated with drug-induced thrombotic microangiopathy. In this abstract, we describe two young patients who lived together and used Opana ER intravenously. Both presented with microangiopathic hemolytic anemia that mimicked thrombotic thrombocytopenic purpura (TTP). Treating this condition poses a clinical challenge, as it is difficult to distinguish it from TTP. The role for plasma exchange is not clear but can be used while awaiting the results of the ADAMTS-13 activity, but ultimately supportive care with drug discontinuation is the recommended therapy of choice. Patients should be counseled against Opana ER’s intravenous use, and users should be offered drug rehabilitation therapy.http://dx.doi.org/10.1155/2017/1623907 |
| spellingShingle | Kamia Thakur Vaibhav Agrawal Ashley Kass Lauren M. Dimarino R. Patrick Dorion Joseph Vadakara Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER Case Reports in Hematology |
| title | Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER |
| title_full | Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER |
| title_fullStr | Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER |
| title_full_unstemmed | Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER |
| title_short | Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER |
| title_sort | thrombotic microangiopathy secondary to intravenous abuse of opana r er |
| url | http://dx.doi.org/10.1155/2017/1623907 |
| work_keys_str_mv | AT kamiathakur thromboticmicroangiopathysecondarytointravenousabuseofopanaer AT vaibhavagrawal thromboticmicroangiopathysecondarytointravenousabuseofopanaer AT ashleykass thromboticmicroangiopathysecondarytointravenousabuseofopanaer AT laurenmdimarino thromboticmicroangiopathysecondarytointravenousabuseofopanaer AT rpatrickdorion thromboticmicroangiopathysecondarytointravenousabuseofopanaer AT josephvadakara thromboticmicroangiopathysecondarytointravenousabuseofopanaer |